Allosteric HIV-1 Integrase Inhibitors Lead to Premature Degradation of the Viral RNA Genome and Integrase in Target Cells

ABSTRACT Recent evidence indicates that inhibition of HIV-1 integrase (IN) binding to the viral RNA genome by allosteric integrase inhibitors (ALLINIs) or through mutations within IN yields aberrant particles in which the viral ribonucleoprotein complexes (vRNPs) are eccentrically localized outside the capsid lattice. These particles are noninfectious and are blocked at an early reverse transcription stage in target cells. However, the basis of this reverse transcription defect is unknown. Here, we show that the viral RNA genome and IN from ALLINI-treated virions are prematurely degraded in target cells, whereas reverse transcriptase remains active and stably associated with the capsid lattice. The aberrantly shaped cores in ALLINI-treated particles can efficiently saturate and be degraded by a restricting TRIM5 protein, indicating that they are still composed of capsid proteins arranged in a hexagonal lattice. Notably, the fates of viral core components follow a similar pattern in cells infected with eccentric particles generated by mutations within IN that inhibit its binding to the viral RNA genome. We propose that IN-RNA interactions allow packaging of both the viral RNA genome and IN within the protective capsid lattice to ensure subsequent reverse transcription and productive infection in target cells. Conversely, disruption of these interactions by ALLINIs or mutations in IN leads to premature degradation of both the viral RNA genome and IN, as well as the spatial separation of reverse transcriptase from the viral genome during early steps of infection. IMPORTANCE Recent evidence indicates that HIV-1 integrase (IN) plays a key role during particle maturation by binding to the viral RNA genome. Inhibition of IN-RNA interactions yields aberrant particles with the viral ribonucleoprotein complexes (vRNPs) eccentrically localized outside the conical capsid lattice. Although these particles contain all of the components necessary for reverse transcription, they are blocked at an early reverse transcription stage in target cells. To explain the basis of this defect, we tracked the fates of multiple viral components in infected cells. Here, we show that the viral RNA genome and IN in eccentric particles are prematurely degraded, whereas reverse transcriptase remains active and stably associated within the capsid lattice. We propose that IN-RNA interactions ensure the packaging of both vRNPs and IN within the protective capsid cores to facilitate subsequent reverse transcription and productive infection in target cells.

[1]  F. Bushman,et al.  Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase , 2016, PLoS biology.

[2]  P. Bieniasz,et al.  HIV-1 Integrase Binds the Viral RNA Genome and Is Essential during Virion Morphogenesis , 2016, Cell.

[3]  S. L. Le Grice,et al.  Interaction between Reverse Transcriptase and Integrase Is Required for Reverse Transcription during HIV-1 Replication , 2015, Journal of Virology.

[4]  A. Engelman,et al.  Distribution and Redistribution of HIV-1 Nucleocapsid Protein in Immature, Mature, and Integrase-Inhibited Virions: a Role for Integrase in Maturation , 2015, Journal of Virology.

[5]  J. Briggs,et al.  RNA and Nucleocapsid Are Dispensable for Mature HIV-1 Capsid Assembly , 2015, Journal of Virology.

[6]  P. Bieniasz,et al.  Global Changes in the RNA Binding Specificity of HIV-1 Gag Regulate Virion Genesis , 2014, Cell.

[7]  T. Hope,et al.  Identification of Capsid Mutations That Alter the Rate of HIV-1 Uncoating in Infected Cells , 2014, Journal of Virology.

[8]  A. Das,et al.  The Allosteric HIV-1 Integrase Inhibitor BI-D Affects Virion Maturation but Does Not Influence Packaging of a Functional RNA Genome , 2014, PloS one.

[9]  F. Bushman,et al.  Allosteric Inhibition of Human Immunodeficiency Virus Integrase , 2014, The Journal of Biological Chemistry.

[10]  F. Bushman,et al.  A New Class of Multimerization Selective Inhibitors of HIV-1 Integrase , 2014, PLoS pathogens.

[11]  Araz Jakalian,et al.  Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1. , 2014, ACS medicinal chemistry letters.

[12]  C. Aiken,et al.  HIV-1 uncoating: connection to nuclear entry and regulation by host proteins. , 2014, Virology.

[13]  N. Krogan,et al.  IFI16 DNA Sensor Is Required for Death of Lymphoid CD4 T Cells Abortively Infected with HIV , 2014, Science.

[14]  I. Hurbain,et al.  The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. , 2013, Immunity.

[15]  A. Saïb,et al.  Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage , 2013, Retrovirology.

[16]  L. James,et al.  HIV-1 evades innate immune recognition through specific co-factor recruitment , 2013, Nature.

[17]  S. Yant,et al.  Non-Catalytic Site HIV-1 Integrase Inhibitors Disrupt Core Maturation and Induce a Reverse Transcription Block in Target Cells , 2013, PloS one.

[18]  P. Bieniasz,et al.  Assisted Evolution Enables HIV-1 to Overcome a High TRIM5α-Imposed Genetic Barrier to Rhesus Macaque Tropism , 2013, PLoS pathogens.

[19]  Nan Yan,et al.  Cyclic GMP-AMP Synthase Is an Innate Immune Sensor of HIV and Other Retroviruses , 2013, Science.

[20]  Y. Pommier,et al.  A homology model of HIV-1 integrase and analysis of mutations designed to test the model. , 2013, Journal of molecular biology.

[21]  D. Friedman,et al.  Retrovirus Restriction by TRIM5 Proteins Requires Recognition of Only a Small Fraction of Viral Capsid Subunits , 2013, Journal of Virology.

[22]  C. Weydert,et al.  LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions , 2013, Retrovirology.

[23]  A. Engelman,et al.  The A128T Resistance Mutation Reveals Aberrant Protein Multimerization as the Primary Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors* , 2013, The Journal of Biological Chemistry.

[24]  A. Engelman,et al.  Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation , 2013, Proceedings of the National Academy of Sciences.

[25]  S. Kutluay,et al.  Fates of Retroviral Core Components during Unrestricted and TRIM5-Restricted Infection , 2013, PLoS pathogens.

[26]  F. Diaz-Griffero,et al.  Inhibition of Reverse Transcriptase Activity Increases Stability of the HIV-1 Core , 2012, Journal of Virology.

[27]  W. Sundquist,et al.  HIV-1 assembly, budding, and maturation. , 2012, Cold Spring Harbor perspectives in medicine.

[28]  G. Brewer,et al.  The regulation of mRNA stability in mammalian cells: 2.0. , 2012, Gene.

[29]  A. Gronenborn,et al.  Second-site suppressors of HIV-1 capsid mutations: restoration of intracellular activities without correction of intrinsic capsid stability defects , 2012, Retrovirology.

[30]  A. Engelman,et al.  Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors* , 2012, The Journal of Biological Chemistry.

[31]  Indira Hewlett,et al.  The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability. , 2011, Virology.

[32]  T. Hope,et al.  Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription , 2011, Proceedings of the National Academy of Sciences.

[33]  M. Muesing,et al.  Sequential Deletion of the Integrase (Gag-Pol) Carboxyl Terminus Reveals Distinct Phenotypic Classes of Defective HIV-1 , 2011, Journal of Virology.

[34]  J. Sodroski,et al.  Hexagonal assembly of a restricting TRIM5α protein , 2010, Proceedings of the National Academy of Sciences.

[35]  K. Musier-Forsyth,et al.  Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription , 2010, RNA biology.

[36]  J. Briggs,et al.  Structural Analysis of HIV-1 Maturation Using Cryo-Electron Tomography , 2010, PLoS pathogens.

[37]  A. Marchand,et al.  Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. , 2010, Nature chemical biology.

[38]  P. Bieniasz,et al.  Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles , 2009, Proceedings of the National Academy of Sciences.

[39]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[40]  M. Mcclure,et al.  A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants. , 2009, Journal of virological methods.

[41]  S. Sarafianos,et al.  Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. , 2009, Journal of molecular biology.

[42]  C. Aiken,et al.  Saturation of TRIM5 alpha-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid. , 2006, Virology.

[43]  A. Engelman,et al.  Genetic Analyses of Conserved Residues in the Carboxyl-Terminal Domain of Human Immunodeficiency Virus Type 1 Integrase , 2005, Journal of Virology.

[44]  M. Bock,et al.  Capsid Processing Requirements for Abrogation of Fv1 and Ref1 Restriction , 2005, Journal of Virology.

[45]  A. Engelman,et al.  Class II Integrase Mutants with Changes in Putative Nuclear Localization Signals Are Primarily Blocked at a Postnuclear Entry Step of Human Immunodeficiency Virus Type 1 Replication , 2004, Journal of Virology.

[46]  D. Pérez-Caballero,et al.  APOBEC3G Incorporation into Human Immunodeficiency Virus Type 1 Particles , 2004, Journal of Virology.

[47]  Marc C. Johnson,et al.  The stoichiometry of Gag protein in HIV-1 , 2004, Nature Structural &Molecular Biology.

[48]  M. Magnasco,et al.  Decay rates of human mRNAs: correlation with functional characteristics and sequence attributes. , 2003, Genome research.

[49]  A. Fassati,et al.  Structural Analyses of Purified Human Immunodeficiency Virus Type 1 Intracellular Reverse Transcription Complexes , 2003, Journal of Virology.

[50]  J. Gregg,et al.  Allele-specific Holliday junction formation: a new mechanism of allelic discrimination for SNP scoring. , 2003, Genome research.

[51]  Wesley I. Sundquist,et al.  Functional Surfaces of the Human Immunodeficiency Virus Type 1 Capsid Protein , 2003, Journal of Virology.

[52]  P. Bieniasz,et al.  Restriction of multiple divergent retroviruses by Lv1 and Ref1 , 2003, The EMBO journal.

[53]  A. Engelman,et al.  Nuclear Localization of Human Immunodeficiency Virus Type 1 Preintegration Complexes (PICs): V165A and R166A Are Pleiotropic Integrase Mutants Primarily Defective for Integration, Not PIC Nuclear Import , 2002, Journal of Virology.

[54]  G. Lucero,et al.  A dominant block to HIV-1 replication at reverse transcription in simian cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[55]  P. Bieniasz,et al.  Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Y. Takeuchi,et al.  Restriction of lentivirus in monkeys , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Wesley I. Sundquist,et al.  Formation of a Human Immunodeficiency Virus Type 1 Core of Optimal Stability Is Crucial for Viral Replication , 2002, Journal of Virology.

[58]  J. Kappes,et al.  The Conformation of the Mature Dimeric Human Immunodeficiency Virus Type 1 RNA Genome Requires Packaging of Pol Protein , 2002, Journal of Virology.

[59]  Y. Durocher,et al.  High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. , 2002, Nucleic acids research.

[60]  E. Freed,et al.  Human Immunodeficiency Virus Type 1 N-Terminal Capsid Mutants That Exhibit Aberrant Core Morphology and Are Blocked in Initiation of Reverse Transcription in Infected Cells , 2001, Journal of Virology.

[61]  P. Boyer,et al.  Replication of Phenotypically Mixed Human Immunodeficiency Virus Type 1 Virions Containing Catalytically Active and Catalytically Inactive Reverse Transcriptase , 2001, Journal of Virology.

[62]  A. Rein,et al.  RNA is a structural element in retrovirus particles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[63]  L. Mulder,et al.  Degradation of HIV-1 Integrase by the N-end Rule Pathway* , 2000, The Journal of Biological Chemistry.

[64]  R. Wagner,et al.  Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication. , 2000, Virology.

[65]  W. Sundquist,et al.  Proteolytic refolding of the HIV‐1 capsid protein amino‐terminus facilitates viral core assembly , 1998, The EMBO journal.

[66]  W. Sundquist,et al.  Molecular recognition in the HIV-1 capsid/cyclophilin A complex. , 1997, Journal of molecular biology.

[67]  S. Goff,et al.  The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle , 1996, Journal of virology.

[68]  H. Göttlinger,et al.  Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease , 1996, Journal of virology.

[69]  A. Engelman,et al.  A Soluble Active Mutant of HIV-1 Integrase , 1996, The Journal of Biological Chemistry.

[70]  H. Varmus,et al.  Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection , 1996, Journal of virology.

[71]  A. Engelman,et al.  Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication , 1995, Journal of virology.

[72]  A. Kaplan,et al.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions , 1994, Journal of virology.

[73]  G. Pavlakis,et al.  Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression , 1992, Journal of virology.

[74]  G. Pavlakis,et al.  Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein , 1992, Journal of virology.

[75]  M. Martin,et al.  Identification of posttranscriptionally active inhibitory sequences in human immunodeficiency virus type 1 RNA: novel level of gene regulation , 1991, Journal of virology.

[76]  A. Engelman In vivo analysis of retroviral integrase structure and function. , 1999, Advances in virus research.